Veru (VERU) Interest Expense : $-1.72 Mil (TTM As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Veru Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Veru's interest expense for the three months ended in Dec. 2023 was $ -0.17 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.72 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Veru's Operating Income for the three months ended in Dec. 2023 was $ -8.80 Mil. Veru's Interest Expense for the three months ended in Dec. 2023 was $ -0.17 Mil. Veru did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Veru Interest Expense Historical Data

The historical data trend for Veru's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Interest Expense Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Interest Expense

Get a 7-Day Free Trial

-4.71

-4.55

-4.85

-4.37

-2.43

Veru Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.87	-0.70	-0.65	-0.21	-0.17

Veru Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.72 Mil.

Veru (NAS:VERU) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Veru's Interest Expense for the three months ended in Dec. 2023 was $-0.17 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-8.80 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $12.34 Mil.

Veru's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Veru did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Veru (VERU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Executives

Mario Eisenberger	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch	director, 10 percent owner	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun	director	48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner	director, 10 percent owner, officer: President and CEO	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco	officer: VP and CFO	515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro	director	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr	officer: CEO of FHC Division	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz	director	2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines	officer: CFO and COO	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune	director	THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish	director, officer: Chairman/Chief Exec. Officer